Kineta Presents New Preclinical Data on VISTA Antagonist Antibodies at AACR Special Conference on Tumor Immunology and Immunotherapy
Kineta Presents New Preclinical Data on VISTA Antagonist Antibodies at AACR Conference on Tumor Immunology and Immunotherapy Seattle, WA -- (October 20, 2020) Kineta, Inc., a clinical stage biotechno ...
Highly Potent Fully Human anti-VISTA Antibodies A New Target Checkpoint Inhibitor against Immunosuppressive Myeloid Cells
Thierry Guillaudeux, PhD, Chief Scientific Officer American Association for Cancer Research (AACR) Virtual Special Conference: Tumor Immunology and Immunotherapy | October 19-20, 2020
Kineta to Extend Research Collaboration with Genentech to Develop a Novel Non-Opioid
Collaboration to advance a first-in-class α9/α10 nAchR antagonist for the treatment of chronic pain into Phase 1 clinical trials Seattle, WA -- (October 7, 2020) Kineta Chronic Pain, LLC, a subsidi ...
Kineta to Participate in BIO Investor Forum Digital
Kineta to Participate in BIO Investor Forum Digital Seattle, WA -- (October 2, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncolo ...
Kineta Invited to Present at August 2020 Investor Conferences
Kineta Invited to Present at August 2020 Investor Conferences Seattle, WA -- (July 30, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies i ...
Kineta Announces Formation of New Immuno-oncology Focused Scientific Advisory Board
Kineta Announces Formation of New Immuno-oncology Focused Scientific Advisory Board Seattle, WA -- (April 21, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of ...